Indian arm of Pfizer Inc.; makes and markets branded vaccines, anti-infectives and internal-medicine drugs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves | 3.4k | 2.3k | 2.8k | 3.2k | 3.5k | 4.2k | 3.8k | 4.2k |
| Borrowings | 2 | 63 | 39 | 41 | 40 | 108 | 43 | 70 |
| Other Liabilities | 1.0k | 810 | 997 | 752 | 593 | 585 | 714 | 649 |
| Total Liabilities | 4.4k | 3.3k | 3.9k | 4.0k | 4.2k | 4.9k | 4.6k | 4.9k |
| AssetsFixed Assets | 973 | 894 | 869 | 749 | 713 | 724 | 701 | 678 |
| CWIP | 1 | 3 | 1 | 8 | 0 | 8 | 8 | 20 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 3.4k | 2.4k | 3.0k | 3.2k | 3.5k | 4.2k | 3.9k | 4.2k |
| Total Assets | 4.4k | 3.3k | 3.9k | 4.0k | 4.2k | 4.9k | 4.6k | 4.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 98 | 323 | 427 | 667 | 356 | 257 | 660 | 968 |
| Cash from Investing | 35 | 1.5k | -469 | -575 | -36 | 54 | -71 | -562 |
| Cash from Financing | -110 | -164 | -1.6k | -181 | -346 | -235 | -205 | -798 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 125 | 343 | 410 | 654 | 292 | 291 | 783 | 944 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (34.7×) and current (29.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 16.7% growth and a 29× exit, ₹4624 only delivers your return if you pay ₹4,398. The price is currently baking in 18% growth.
EPS grows 16.7%/yr for 5 years, then fades to 6% over 2, exits at 29×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 16.7% | 184.28 |
| FY28 | 16.7% | 215.06 |
| FY29 | 16.7% | 250.97 |
| FY30 | 16.7% | 292.88 |
| FY31 | 16.7% | 341.79 |
| FY32 | 11.3% ·fade | 380.59 |
| FY33 | 6.0% ·fade | 403.42 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.